Abstract
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, evaluates a study showing activity by pralsetinib in patients with a variety of tumors harboring RET gene fusions, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of University of Arizona Cancer Center, comments on the effect of deintensification in patients with intermediate-risk HPV-positive oropharyngeal cancer. Meeting coverage is provided by The ASCO Post.